gutflix
GI learning, personalised

Summary

EFFECT OF TOFACITINIB ON COLECTOMY RISK IN ANTI TNF-ALFA REFRACTORY ULCERATIVE COLITIS

Saverio Alicante

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A multicenter Italian study of 45 patients with moderate-to-severe ulcerative colitis refractory to anti-TNF agents found tofacitinib prevented colectomy in 87% of patients over 52 weeks.

KEY POINTS

- Six patients (13%) underwent colectomy during follow-up, all occurring before week 24
- Clinical remission rates increased over time: 37.7% at week 8, 44.4% at week 24, and 48.8% at week 52
- Among 11 patients with endoscopic evaluation at 52 weeks, 9 (82%) achieved endoscopic remission
- Adverse events occurred in 9 patients (20%), with only 3 (6.7%) experiencing severe events requiring treatment discontinuation
- The study included patients with moderate-to-severe UC (Mayo score ≥ 6) who had failed or were intolerant to anti-TNF agents

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/3c8052c4-743b-11ee-9631-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.